EHA 2021: updates on novel agents for AML

A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older age and the presence of comorbidities, creating an unmet medical need. Recent advances in the understanding of the genomics underlying AML have led to the development of therapies targeting FLT3, IDH1/2 and BCL-2. Between 2017 and 2018 the US FDA approved a total of eight drugs for AML, including glasdegib, venetoclax, ivosidenib, midostaurin and gemtuzumab ozogamicin. Many trials are now reporting longer follow-up data on these drugs as well as on novel combinations and approaches.

In this podcast, Andrew Brunner, MD, of the Massachusetts General Hospital, Boston, MA, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Stéphane de Botton, MD, PhD, of the Gustave Roussy Institute, Paris, France, and Andrius Zucenka, MD, of the Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, share updates on novel therapies for the treatment of AML, as presented at the European Hematology Association (EHA) 2021 congress.